RecruitingPhase 3NCT05696613
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Studying Primary membranous glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cerium Pharmaceuticals, Inc.
- Intervention
- SNP-ACTH (1-39) Gel(drug)
- Enrollment
- 148 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Academic Medical Research Institute, Los Angeles, California, United States
- North America Research Institute, San Dimas, California, United States
- Valiance Clinical Research, Tarzana, California, United States
- RecioMed Clinical Research Network, Inc., Boynton Beach, Florida, United States
- South Florida Nephrology Research, Coral Springs, Florida, United States
- Therafirst Medical Center, Fort Lauderdale, Florida, United States
- Reliant Medical Research, LLC, Miami, Florida, United States
- Vista Health Research, LLC, Miami, Florida, United States
- Genesis Clinical Research, Tampa, Florida, United States
- Fides Clinical Research, Atlanta, Georgia, United States
- Costal Medical Research, Brunswick, Georgia, United States
- Insight Hospital and Medical Center Chicago, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Center for Advanced Kidney Research, PLC, Saint Clair Shores, Michigan, United States
- NYU Langone Health, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05696613 on ClinicalTrials.govOther trials for Primary membranous glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07289763Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2, PHASE3NCT07204275A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE2NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)Alexion Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT07096843A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyClimb Bio, Inc.
- RECRUITINGPHASE3NCT06962800A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Biogen
- RECRUITINGPHASE1NCT06982729Study of YK012 in Primary Membranous NephropathyExcyte Biopharma Ltd
- RECRUITINGNCT06242327An Outcome Analysis of Primary Membranous NephropathyMario Negri Institute for Pharmacological Research
- ACTIVE NOT RECRUITINGPHASE2NCT06642909A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyBioRay Pharmaceutical Co., Ltd.